A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects

Condition: Asthma
Intervention: Biological: Mepolizumab
Sponsor: GlaxoSmithKline
Not yet recruiting – verified May 2014

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

Posted

May 14, 2014

in

Asthma Clinical Trials U.S.

by

lowes1

Tags:

Asthmatic, Dose, Longterm, Mepolizumab, OpenLabel, Phase, Repeat, safety, Study, subjects

Comments

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.